Market Cap | 88.63M | P/E | - | EPS this Y | 32.30% | Ern Qtrly Grth | - |
Income | -83.8M | Forward P/E | -1.37 | EPS next Y | 38.10% | 50D Avg Chg | -27.00% |
Sales | 9.85M | PEG | - | EPS past 5Y | -1.34% | 200D Avg Chg | -34.00% |
Dividend | N/A | Price/Book | 1.11 | EPS next 5Y | - | 52W High Chg | -69.00% |
Recommedations | 3.00 | Quick Ratio | 0.21 | Shares Outstanding | 272.84M | 52W Low Chg | 32.00% |
Insider Own | 2.06% | ROA | -76.18% | Shares Float | 245.78M | Beta | 1.38 |
Inst Own | 18.27% | ROE | -334.02% | Shares Shorted/Prior | 11.29M/11.32M | Price | 0.37 |
Gross Margin | -30.45% | Profit Margin | - | Avg. Volume | 1,311,158 | Target Price | 0.35 |
Oper. Margin | -808.43% | Earnings Date | Nov 12 | Volume | 1,712,418 | Change | 1.70% |
Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients. The company's products include Senhance System, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures; instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. is headquartered in Durham, North Carolina.
HC Wainwright & Co. | Neutral | May 16, 24 |
HC Wainwright & Co. | Neutral | Apr 4, 24 |
HC Wainwright & Co. | Buy | Mar 22, 24 |
Cantor Fitzgerald | Neutral | Nov 16, 23 |
HC Wainwright & Co. | Buy | Nov 15, 23 |
Cantor Fitzgerald | Overweight | Aug 22, 23 |
HC Wainwright & Co. | Buy | Aug 11, 23 |
HC Wainwright & Co. | Buy | May 12, 23 |
HC Wainwright & Co. | Buy | Mar 6, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Starling William N JR | Director Director | Dec 14 | Sell | 0.28 | 18,134 | 5,078 | 12/18/23 | |
Starling William N JR | Director Director | Dec 14 | Buy | 0.28 | 18,134 | 5,078 | 39,134 | 12/18/23 |
Biffi Andrea | Director Director | Mar 03 | Buy | 0.7082 | 293,077 | 207,557 | 492,815 | 03/07/23 |
Starling William N JR | Director Director | Jun 13 | Sell | 0.40 | 27,010 | 10,804 | 13,846 | 06/15/22 |
Kwo Elizabeth | Director Director | Mar 15 | Buy | 0.531 | 18,000 | 9,558 | 72,201 | 03/16/22 |
Milne David Bruce | Director Director | Mar 04 | Buy | 0.63 | 375,000 | 236,250 | 619,884 | 03/08/22 |